Competing actions of type 1 angiotensin II receptors expressed on t lymphocytes and kidney epithelium during cisplatin-induced aki

Jiandong Zhang, Nathan P. Rudemiller, Mehul B. Patel, Qingqing Wei, Norah S. Karlovich, Alexander D. Jeffs, Min Wu, Matthew A. Sparks, Jamie R. Privratsky, Marcela Herrera, Susan Gurley, Sergei A. Nedospasov, Steven D. Crowley

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Inappropriate activation of the renin-angiotensin system (RAS) contributes to many CKDs. However, the role of the RAS in modulating AKI requires elucidation, particularly because stimulating type 1 angiotensin II (AT1) receptors in the kidney or circulating inflammatory cells can have opposing effects on the generation of inflammatory mediators that underpin the pathogenesis of AKI. For example, TNF-a is a fundamental driver of cisplatin nephrotoxicity, and generation of TNF-a is suppressed or enhanced by AT1 receptor signaling in T lymphocytes or the distal nephron, respectively. In this study, cell tracking experiments with CD4-Cre mT/mG reporter mice revealed robust infiltration of T lymphocytes into the kidney after cisplatin injection. Notably, knockout of AT1 receptors on T lymphocytes exacerbated the severity of cisplatin-induced AKI and enhanced the cisplatin-induced increase in TNF-a levels locally within the kidney and in the systemic circulation. In contrast, knockout of AT1 receptors on kidney epithelial cells ameliorated the severity of AKI and suppressed local and systemic TNF-a production induced by cisplatin. Finally, disrupting TNF-a production specifically within the renal tubular epithelium attenuated the AKI and the increase in circulating TNF-a levels induced by cisplatin. These results illustrate discrepant tissue-specific effects of RAS stimulation on cisplatin nephrotoxicity and raise the concern that inflammatorymediators produced by renal parenchymal cellsmay influence the function of remote organs by altering systemic cytokine levels. Our findings suggest selective inhibition of AT1 receptors within the nephron as a promising intervention for protecting patients from cisplatin-induced nephrotoxicity.

Original languageEnglish (US)
Pages (from-to)2257-2264
Number of pages8
JournalJournal of the American Society of Nephrology
Volume27
Issue number8
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Angiotensin Type 1 Receptor
Cisplatin
Epithelium
Lymphocytes
Kidney
Renin-Angiotensin System
Nephrons
T-Lymphocytes
Cell Tracking
Cohort Effect
Angiotensin Receptors
Epithelial Cells
Cytokines
Injections

ASJC Scopus subject areas

  • Nephrology

Cite this

Competing actions of type 1 angiotensin II receptors expressed on t lymphocytes and kidney epithelium during cisplatin-induced aki. / Zhang, Jiandong; Rudemiller, Nathan P.; Patel, Mehul B.; Wei, Qingqing; Karlovich, Norah S.; Jeffs, Alexander D.; Wu, Min; Sparks, Matthew A.; Privratsky, Jamie R.; Herrera, Marcela; Gurley, Susan; Nedospasov, Sergei A.; Crowley, Steven D.

In: Journal of the American Society of Nephrology, Vol. 27, No. 8, 01.01.2016, p. 2257-2264.

Research output: Contribution to journalArticle

Zhang, J, Rudemiller, NP, Patel, MB, Wei, Q, Karlovich, NS, Jeffs, AD, Wu, M, Sparks, MA, Privratsky, JR, Herrera, M, Gurley, S, Nedospasov, SA & Crowley, SD 2016, 'Competing actions of type 1 angiotensin II receptors expressed on t lymphocytes and kidney epithelium during cisplatin-induced aki', Journal of the American Society of Nephrology, vol. 27, no. 8, pp. 2257-2264. https://doi.org/10.1681/ASN.2015060683
Zhang, Jiandong ; Rudemiller, Nathan P. ; Patel, Mehul B. ; Wei, Qingqing ; Karlovich, Norah S. ; Jeffs, Alexander D. ; Wu, Min ; Sparks, Matthew A. ; Privratsky, Jamie R. ; Herrera, Marcela ; Gurley, Susan ; Nedospasov, Sergei A. ; Crowley, Steven D. / Competing actions of type 1 angiotensin II receptors expressed on t lymphocytes and kidney epithelium during cisplatin-induced aki. In: Journal of the American Society of Nephrology. 2016 ; Vol. 27, No. 8. pp. 2257-2264.
@article{909ae86ded7c40a7bb5a587926ba7db1,
title = "Competing actions of type 1 angiotensin II receptors expressed on t lymphocytes and kidney epithelium during cisplatin-induced aki",
abstract = "Inappropriate activation of the renin-angiotensin system (RAS) contributes to many CKDs. However, the role of the RAS in modulating AKI requires elucidation, particularly because stimulating type 1 angiotensin II (AT1) receptors in the kidney or circulating inflammatory cells can have opposing effects on the generation of inflammatory mediators that underpin the pathogenesis of AKI. For example, TNF-a is a fundamental driver of cisplatin nephrotoxicity, and generation of TNF-a is suppressed or enhanced by AT1 receptor signaling in T lymphocytes or the distal nephron, respectively. In this study, cell tracking experiments with CD4-Cre mT/mG reporter mice revealed robust infiltration of T lymphocytes into the kidney after cisplatin injection. Notably, knockout of AT1 receptors on T lymphocytes exacerbated the severity of cisplatin-induced AKI and enhanced the cisplatin-induced increase in TNF-a levels locally within the kidney and in the systemic circulation. In contrast, knockout of AT1 receptors on kidney epithelial cells ameliorated the severity of AKI and suppressed local and systemic TNF-a production induced by cisplatin. Finally, disrupting TNF-a production specifically within the renal tubular epithelium attenuated the AKI and the increase in circulating TNF-a levels induced by cisplatin. These results illustrate discrepant tissue-specific effects of RAS stimulation on cisplatin nephrotoxicity and raise the concern that inflammatorymediators produced by renal parenchymal cellsmay influence the function of remote organs by altering systemic cytokine levels. Our findings suggest selective inhibition of AT1 receptors within the nephron as a promising intervention for protecting patients from cisplatin-induced nephrotoxicity.",
author = "Jiandong Zhang and Rudemiller, {Nathan P.} and Patel, {Mehul B.} and Qingqing Wei and Karlovich, {Norah S.} and Jeffs, {Alexander D.} and Min Wu and Sparks, {Matthew A.} and Privratsky, {Jamie R.} and Marcela Herrera and Susan Gurley and Nedospasov, {Sergei A.} and Crowley, {Steven D.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1681/ASN.2015060683",
language = "English (US)",
volume = "27",
pages = "2257--2264",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "8",

}

TY - JOUR

T1 - Competing actions of type 1 angiotensin II receptors expressed on t lymphocytes and kidney epithelium during cisplatin-induced aki

AU - Zhang, Jiandong

AU - Rudemiller, Nathan P.

AU - Patel, Mehul B.

AU - Wei, Qingqing

AU - Karlovich, Norah S.

AU - Jeffs, Alexander D.

AU - Wu, Min

AU - Sparks, Matthew A.

AU - Privratsky, Jamie R.

AU - Herrera, Marcela

AU - Gurley, Susan

AU - Nedospasov, Sergei A.

AU - Crowley, Steven D.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Inappropriate activation of the renin-angiotensin system (RAS) contributes to many CKDs. However, the role of the RAS in modulating AKI requires elucidation, particularly because stimulating type 1 angiotensin II (AT1) receptors in the kidney or circulating inflammatory cells can have opposing effects on the generation of inflammatory mediators that underpin the pathogenesis of AKI. For example, TNF-a is a fundamental driver of cisplatin nephrotoxicity, and generation of TNF-a is suppressed or enhanced by AT1 receptor signaling in T lymphocytes or the distal nephron, respectively. In this study, cell tracking experiments with CD4-Cre mT/mG reporter mice revealed robust infiltration of T lymphocytes into the kidney after cisplatin injection. Notably, knockout of AT1 receptors on T lymphocytes exacerbated the severity of cisplatin-induced AKI and enhanced the cisplatin-induced increase in TNF-a levels locally within the kidney and in the systemic circulation. In contrast, knockout of AT1 receptors on kidney epithelial cells ameliorated the severity of AKI and suppressed local and systemic TNF-a production induced by cisplatin. Finally, disrupting TNF-a production specifically within the renal tubular epithelium attenuated the AKI and the increase in circulating TNF-a levels induced by cisplatin. These results illustrate discrepant tissue-specific effects of RAS stimulation on cisplatin nephrotoxicity and raise the concern that inflammatorymediators produced by renal parenchymal cellsmay influence the function of remote organs by altering systemic cytokine levels. Our findings suggest selective inhibition of AT1 receptors within the nephron as a promising intervention for protecting patients from cisplatin-induced nephrotoxicity.

AB - Inappropriate activation of the renin-angiotensin system (RAS) contributes to many CKDs. However, the role of the RAS in modulating AKI requires elucidation, particularly because stimulating type 1 angiotensin II (AT1) receptors in the kidney or circulating inflammatory cells can have opposing effects on the generation of inflammatory mediators that underpin the pathogenesis of AKI. For example, TNF-a is a fundamental driver of cisplatin nephrotoxicity, and generation of TNF-a is suppressed or enhanced by AT1 receptor signaling in T lymphocytes or the distal nephron, respectively. In this study, cell tracking experiments with CD4-Cre mT/mG reporter mice revealed robust infiltration of T lymphocytes into the kidney after cisplatin injection. Notably, knockout of AT1 receptors on T lymphocytes exacerbated the severity of cisplatin-induced AKI and enhanced the cisplatin-induced increase in TNF-a levels locally within the kidney and in the systemic circulation. In contrast, knockout of AT1 receptors on kidney epithelial cells ameliorated the severity of AKI and suppressed local and systemic TNF-a production induced by cisplatin. Finally, disrupting TNF-a production specifically within the renal tubular epithelium attenuated the AKI and the increase in circulating TNF-a levels induced by cisplatin. These results illustrate discrepant tissue-specific effects of RAS stimulation on cisplatin nephrotoxicity and raise the concern that inflammatorymediators produced by renal parenchymal cellsmay influence the function of remote organs by altering systemic cytokine levels. Our findings suggest selective inhibition of AT1 receptors within the nephron as a promising intervention for protecting patients from cisplatin-induced nephrotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=85015765031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015765031&partnerID=8YFLogxK

U2 - 10.1681/ASN.2015060683

DO - 10.1681/ASN.2015060683

M3 - Article

C2 - 26744488

AN - SCOPUS:85015765031

VL - 27

SP - 2257

EP - 2264

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 8

ER -